Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): A systematic review and meta-analysis
Medicine · 2026 Oct 23 · Alfawaz M, Bajamaan D, Alghamdi L et
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 22 20:00 ETSource: Medicine
From the source
Read at pubmed.ncbi.nlm.nih.govEfficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): A systematic review and meta-analysis
Medicine · 2026 Oct 23 · Alfawaz M, Bajamaan D, Alghamdi L et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42937793/
